Prognostic role of vascular endothelial growth factor and its receptor-1 in patients with esophageal cancer
Standard
Prognostic role of vascular endothelial growth factor and its receptor-1 in patients with esophageal cancer. / Kilic, Ergin; Schild, Steven E; Thorns, Christoph; Bajrovic, Amira; Rades, Dirk.
In: ANTICANCER RES, Vol. 34, No. 9, 09.2014, p. 5221-6.Research output: SCORING: Contribution to journal › SCORING: Journal article › Research › peer-review
Harvard
APA
Vancouver
Bibtex
}
RIS
TY - JOUR
T1 - Prognostic role of vascular endothelial growth factor and its receptor-1 in patients with esophageal cancer
AU - Kilic, Ergin
AU - Schild, Steven E
AU - Thorns, Christoph
AU - Bajrovic, Amira
AU - Rades, Dirk
N1 - Copyright© 2014 International Institute of Anticancer Research (Dr. John G. Delinassios), All rights reserved.
PY - 2014/9
Y1 - 2014/9
N2 - BACKGROUND/AIM: To present long-term results regarding the role of vascular endothelial growth factor (VEGF) and its receptor-1 (VEGFR-1) for esophageal cancer.PATIENTS AND METHODS: In 68 esophageal cancer patients, VEGF, VEGFR-1 plus ten other factors were analyzed for locoregional control (LRC), metastases-free survival (MFS) and survival up to 10 years.RESULTS: On multivariate analysis, improved LRC was associated with hemoglobin during radiotherapy ≥12 g/dl (p=0.001). VEGF-negativity showed a trend for better LRC on univariate analysis. On multivariate analysis, better MFS was associated with hemoglobin ≥12 g/dl (p=0.012), better performance status (p=0.009) and lower tumor stage (p=0.032). On multivariate analysis, improved survival was associated with hemoglobin ≥12 g/dl (p<0.001) and better performance status (p=0.005). Trends for improved survival were observed for VEGF-negativity and VEGFR-1-negativity on univariate analysis.CONCLUSION: VEGF showed a trend towards worse LRC and survival, VEGFR-1 towards worse survival. Outcomes were associated with hemoglobin, performance status and tumor stage.
AB - BACKGROUND/AIM: To present long-term results regarding the role of vascular endothelial growth factor (VEGF) and its receptor-1 (VEGFR-1) for esophageal cancer.PATIENTS AND METHODS: In 68 esophageal cancer patients, VEGF, VEGFR-1 plus ten other factors were analyzed for locoregional control (LRC), metastases-free survival (MFS) and survival up to 10 years.RESULTS: On multivariate analysis, improved LRC was associated with hemoglobin during radiotherapy ≥12 g/dl (p=0.001). VEGF-negativity showed a trend for better LRC on univariate analysis. On multivariate analysis, better MFS was associated with hemoglobin ≥12 g/dl (p=0.012), better performance status (p=0.009) and lower tumor stage (p=0.032). On multivariate analysis, improved survival was associated with hemoglobin ≥12 g/dl (p<0.001) and better performance status (p=0.005). Trends for improved survival were observed for VEGF-negativity and VEGFR-1-negativity on univariate analysis.CONCLUSION: VEGF showed a trend towards worse LRC and survival, VEGFR-1 towards worse survival. Outcomes were associated with hemoglobin, performance status and tumor stage.
KW - Adult
KW - Aged
KW - Esophageal Neoplasms
KW - Female
KW - Follow-Up Studies
KW - Humans
KW - Male
KW - Middle Aged
KW - Neoplasm Grading
KW - Neoplasm Staging
KW - Prognosis
KW - Treatment Outcome
KW - Vascular Endothelial Growth Factor A
KW - Vascular Endothelial Growth Factor Receptor-1
M3 - SCORING: Journal article
C2 - 25202119
VL - 34
SP - 5221
EP - 5226
JO - ANTICANCER RES
JF - ANTICANCER RES
SN - 0250-7005
IS - 9
ER -
